FMP

FMP

Enter

PIRS - Pieris Pharmace...

photo-url-https://images.financialmodelingprep.com/symbol/PIRS.png

Pieris Pharmaceuticals, Inc.

PIRS

NASDAQ

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

16.33 USD

-0.35 (-2.14%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Stephen S. Yoder J.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; ...

CIK

0001583648

ISIN

US7207951036

CUSIP

720795103

Address

255 State Street

Phone

857 246 8998

Country

US

Employee

46

IPO Date

Jan 2, 2015

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

PIRS Financial Summary

CIK

0001583648

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

720795103

ISIN

US7207951036

Country

US

Price

16.33

Beta

0.66

Volume Avg.

18.6k

Market Cap

21.56M

Shares

-

52-Week

6.2-22.32

DCF

-9.52

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.38

P/B

-

Website

https://www.pieris.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest PIRS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep